Compounding pharmacies in Minnesota
By the PeptideAgent Editorial Team. Editorially reviewed, not clinically reviewed. Last verified
The Minnesota Board of Pharmacy regulates compounding pharmacies in Minnesota. Compounded GLP-1 limited. How to check a pharmacy's license, plus listings with their verification status.
Minnesota at a glance
- Pharmacy regulator
- Minnesota Board of Pharmacy
- 503A framework
- Follows the federal 503A framework
- Telehealth prescribing
- Regulatory: Telehealth allowed
- Asynchronous prescribing
- Regulatory: Async unclear
- Compounded GLP-1 access
- Regulatory: Compounded GLP-1 limited
Compounding pharmacies serving Minnesota
No verified compounding pharmacies serving Minnesota are listed yet. A provider appears here only after it passes the verification checklist, and those checks are still under way.
Looking for care now? Start with what the law allows where you live, then how a legitimate prescription works.
Run a pharmacy, clinic, or telehealth service? Apply for a listing.
Who regulates compounding pharmacies in Minnesota
The Minnesota Board of Pharmacy licenses pharmacies under Minn. Stat. chapter 151 (the Pharmacy Practice and Wholesale Distribution Act) and regulates practice through Minnesota Rules chapter 6800. Under section 151.19, a pharmacy located outside Minnesota that dispenses to Minnesota residents and ships prescription drugs into the state must hold a Minnesota nonresident pharmacy license, disclose its home-state licensure, and name the pharmacists dispensing to Minnesota patients; the Board also requires a nonresident pharmacist-in-charge designation. Minnesota has no state bulks list; peptide eligibility follows the federal 503A framework. The Board's published guidance documents and its compounding FAQ page, checked on 2026-09-22, do not address semaglutide salt forms or research-grade ingredients, so this record makes no Minnesota-specific claim about them; the federal 503A limits apply. [1] [5] [6] [8] [9] [10] [11]
Compounded GLP-1 access in Minnesota
Minnesota's statutory examination requirement in section 151.37 does not list GLP-1s, so the main state-specific checks are a Minnesota-licensed prescriber, or a physician registered for interstate telehealth under Minn. Stat. section 147.032, and a pharmacy holding a Minnesota or nonresident Minnesota license. Minnesota law does not settle whether the evaluation can happen without a live visit. [2] [3] [4] [6] [14]
Research use only sellers in Minnesota
Minn. Stat. section 151.34 prohibits manufacturing, selling, or delivering adulterated or misbranded drugs and selling legend drugs without a prescription in Minnesota. [7] [15]
Minnesota notes on specific peptides
- Semaglutide: Available branded by prescription, including by telehealth; it is not one of the drugs for which Minn. Stat. section 151.37 requires a documented examination. Compounded semaglutide is limited to the federal patient specific exception since the 503A grace period ended April 22, 2025. [2] [14]
How to check a compounding pharmacy in Minnesota
- Search the Minnesota Board of Pharmacy license lookup for the pharmacy by name. A pharmacy based elsewhere needs whatever license or registration Minnesota requires before it ships to you. [1] [5] [6] [8] [9] [10] [11]
- Ask whether it operates as a 503A pharmacy or a 503B outsourcing facility, and confirm a 503B claim against FDA's outsourcing facility information (see the verification checklist).
- Confirm the peptide can be lawfully compounded: check its status on the regulatory tracker or its peptide page before paying.
- Walk away from any seller that labels a peptide "research use only" or "not for human consumption". See the research use only section above for what that means in Minnesota. [7] [15]
Common questions in Minnesota
Can an out-of-state pharmacy ship compounded peptides to me in Minnesota?
Only if it holds a Minnesota nonresident pharmacy license under Minn. Stat. section 151.19. Search the Board of Pharmacy license lookup before ordering. [1] [6]
Can a Minnesota pharmacy compound BPC-157?
Only under a draft federal policy, and only within strict limits. On October 28, 2026 HHS released a draft enforcement discretion policy saying it will not take enforcement action against a state-licensed pharmacy that compounds BPC-157 as a single-ingredient product by an allowed route, on a patient-specific prescription, from an FDA-registered manufacturer's substance with a tested certificate of analysis, with serious adverse events reported to FDA. BPC-157 is still not FDA approved or on the 503A bulks list, the policy is not binding and HHS may revisit it, and blends such as Wolverine are not covered. FDA's drug center recommended against listing BPC-157; the advisory committee voted in favor (HHS policy, Appendix B). State law still applies: Minnesota has no state bulks list; peptide eligibility follows the federal 503A framework. [11] [12] [13] [16] [17]
Sources
- [1]Minnesota Board of Pharmacy
- [2]Minnesota Statutes section 151.37, Legend drugs; who may prescribe, possess
- [3]Minnesota Statutes section 62A.673, Coverage of services provided through telehealth (Minnesota Telehealth Act)
- [4]Minnesota Statutes section 147.032, Interstate practice of telemedicine
- [5]Minnesota Statutes chapter 151, Pharmacy Practice and Wholesale Distribution Act
- [6]Minnesota Statutes section 151.19, Pharmacy licensure requirements (including nonresident pharmacies)
- [7]Minnesota Statutes section 151.34, Prohibited acts
- [8]Minnesota Rules chapter 6800, Pharmacy and pharmacists
- [9]Minnesota Board of Pharmacy: guidance documents
- [10]Minnesota Board of Pharmacy: compounding FAQs